1. Summary Information
|
|
|
Country |
India |
|
Company Name |
IND SWIFT
LABORATORIES LIMITED |
Principal Name 1 |
Mr. V. K. Mehta |
|
Status |
Good |
Principal Name 2 |
Mr. S. R. Mehta |
|
|
|
Registration # |
16-15553 |
|
Street Address |
S.C.O. 850,
Shivalik Enclave, N.A.C., Manimajra, Chandigarh – 160 101, India |
||
|
Established Date |
04.01.1995 |
SIC Code |
-- |
|
Telephone# |
91-172-2660918 /
2604934 / 2730503 |
Business Style 1 |
Manufacturing |
|
Fax # |
91-172-2660920 /
2730504 |
Business Style 2 |
-- |
|
Homepage |
Product Name 1 |
Pharmaceutical products |
|
|
# of employees |
1200
(Approximately) |
Product Name 2 |
Norfloxacin |
|
Paid up capital |
Rs.278,524,000 |
Product Name 3 |
Ampicillin |
|
Shareholders |
Promoter and Promoters
Group – 43.72% Public Shareholding –
56.28% |
Banking |
State
Bank of India |
|
Public Limited Corp. |
YES |
Business Period |
16 years |
|
IPO |
YES |
International Ins. |
-- |
|
Public |
YES |
Rating |
A
(64) |
|
Related
Company |
|||
|
Relation
|
Country
|
Company
Name |
CEO |
|
Associates |
India
|
Swift
Fundamental Research and Education Society |
-- |
|
Note |
- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2010 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
3,178,552,000 |
Current Liabilities |
5,550,974,000 |
|
Inventories |
2,372,422,000 |
Long-term Liabilities |
5,883,263,000
|
|
Fixed Assets |
4,787,508,000 |
Other Liabilities |
438,003,000 |
|
Deferred Assets |
0.000 |
Total Liabilities |
11,872,240,000 |
|
Invest& other Assets |
2,412,040,000 |
Retained Earnings |
4,204,794,000 |
|
|
|
Net Worth |
4,520,818,000 |
|
Total Assets |
16,393,058,000 |
Total Liab. & Equity |
16,393,058,000 |
|
Total Assets (Previous Year) |
9,915,300,000 |
|
|
|
P/L Statement as of |
31.03.2010 |
(Unit: Indian Rs.) |
|
|
Sales |
7,835,520,000 |
Net Profit |
579,639,000 |
|
Sales(Previous yr) |
5,990,008,000 |
Net Profit(Prev.yr) |
397.900,000 |
MIRA
INFORM REPORT
|
Report Date : |
20.09.2011 |
IDENTIFICATION DETAILS
|
Name : |
IND SWIFT LABORATORIES LIMITED |
|
|
|
|
Registered Office : |
S.C.O. 850, Shivalik Enclave, N.A.C., Manimajra, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2010 |
|
|
|
|
Date of Incorporation : |
04.01.1995 |
|
|
|
|
Capital Investment / Paid-up Capital : |
Rs.278.524 millions |
|
|
|
|
Com. Reg. No.: |
16-15553 |
|
|
|
|
CIN No.: [Company
Identification No.] |
L24232CH1995PLC015553 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
PTLI10111D / PTLI10125D |
|
|
|
|
Legal Form : |
A Public Limited Liability Company. The company’s shares are listed on
the stock exchanges. |
|
|
|
|
Line of Business : |
Manufacturing of Pharmaceutical products such as Norfloxacin,
Ampicillin, Amoxycillin, Erythromycin, Roxythromycin, etc. |
|
|
|
|
No. of Employees : |
1200 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
A (64) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 18083200 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having fine track.
Directors are reported to be experienced and respectable businessmen.
Financial position of the company appears sound. Trade relations are reported
as fair. Business is active. Payments are reported to be regular and as per
commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – April 1, 2010
|
Country Name |
Previous Rating |